Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

http://www.wikidata.org/entity/Q28345359

about

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.Letrozole in the treatment of breast cancer.Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.Letrozole for the management of breast cancer.Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Anastrozole in the management of breast cancer.Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.The therapeutic potential of aromatase inhibitors.Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.Understanding the mechanisms of aromatase inhibitor resistance.The adjuvant endocrine treatment revolution: focus on anastrozole.Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.Minireview: nuclear receptors and breast cancer Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.Aromatase inhibitors: prediction of response and nature of resistance.Drug safety evaluation of exemestane.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.The use of aromatase inhibitors in boys with short stature: what to know before prescribing?A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.David Kupfer and the metabolism connection: on aromatase inhibitors and tamoxifen.Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.Is monitoring mean platelet volume necessary in breast cancer patients?

P2860

Q24634011-C066872E-009D-4549-8E91-41E49F180FB0 Q33739214-92C5EFAA-A760-420F-A8BC-53F6FDA344AD Q34156603-B8E23BFF-8BB5-4CAA-A2E1-6D19B05F689D Q34457429-AF040C92-5E2E-4A69-BEEB-263C9E0D554F Q34628632-272BFF23-B629-4C20-92FC-6AE16C484153 Q34720114-2272073F-2E20-4937-8579-6865804F2714 Q34734008-B5DD3CE8-8FC4-45A0-B102-21CF6077DA6D Q34774040-8A78CFA9-EB93-4FF8-85A5-237B8392128A Q34789155-B4028FEB-BF39-4767-8F94-4A2725D45F18 Q35034811-7F7B679D-D54B-4340-A4C4-5871F43F652C Q35073327-FF42F6A9-6A1A-4312-AB33-7579DF03C9B0 Q35846781-AB479DAB-3247-45E1-82D9-6673B5794DFE Q35975826-ED9C6FBA-EDBC-472B-AF7C-802FF09A067B Q36393053-1F1DADD6-3BB2-4564-BD4C-F0A2D8E3E1E4 Q36546281-F0E7FE3A-EFB1-4549-83CC-459C79C1E1A7 Q36567154-4EE02C63-E35D-4EBB-BBB0-8F05370C096A Q36675384-5858A7FD-0C50-422B-8AEE-C959D8EE1198 Q36684423-C97E0841-417B-4D77-B4DF-5C591C983A3E Q36717159-6D5D8B18-DE30-4FAD-B06B-E1542801FAD7 Q36924682-D4596002-C07E-4DBF-93AF-8EB58348E5D2 Q36971797-D809817C-98DA-4B0B-8329-283C4CC78C2C Q37449530-F45AD00F-168A-4AB0-9AC1-29295C3EE02E Q37760220-3AE2AE64-016E-4A1B-AC5B-05EEE3A1FCDE Q37856307-6AA96DD9-954A-45C1-99D8-4AB2C9D40884 Q38103593-6FB240BE-0D82-4801-B285-513081AD7A14 Q38107969-B4686FF8-BE7D-4E86-B243-B89B33B40189 Q38739248-5794F981-A93F-4A46-B661-7D9CAC2D8722 Q38851505-D95A7A5E-2897-493D-8686-615EDE7EE0AA Q39261999-AE23CAEC-EF10-4B7E-8807-454F0EE96EEE Q46192322-9F706B7C-6BB2-44E6-81C7-D2CD68377EBD Q46704736-DACFDF25-4AEB-42DA-9634-2368A0946339 Q47700487-8AF14172-BA8C-40F8-93B5-D52515967142 Q48014012-68F58699-11FA-4B3A-9BF7-52906064903B Q48598107-C6FCD9CD-A595-4D13-B6AB-6C77064795BB Q52850128-49EFE7E8-E281-4C16-8BC2-D9F7B0C39F71 Q58691025-5F4CA232-9F33-4D83-AD0B-290D1B3814F1

P2860

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

http://www.wikidata.org/entity/Q28345359

description

2001 nî lūn-bûn

@nan

2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@ast

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@en

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@nl

type

label

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@ast

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@en

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@nl

prefLabel

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@ast

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@en

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@nl

P1433

Q28345359-0FDD3B1A-5E94-43EC-A779-447F2626CC74

P1476

Q28345359-A0C4608F-4969-4F09-929D-4CB35B7A6280

P2093

Q28345359-3FD79766-E5A0-4E7A-8EF1-7CE82B2ED731

Q28345359-42FF37E7-5054-46CE-8AF6-9F0E41EA9517

Q28345359-C70119A8-4F40-49A4-B452-7BF2B7A964C7

Q28345359-E087853D-F6CB-45B9-9430-C8B23825BD47

P2860

Q28345359-14CA2061-797F-4632-ACE8-6A4FD108B2E7

Q28345359-489D2D5C-EDE7-4F02-A45C-422E078A01C7

Q28345359-61118CC0-60A3-4E80-A2D3-6932337BD500

Q28345359-6DE6D83F-E362-44D6-AE7A-102E693B1BC1

Q28345359-72E3ED4D-BCF2-4648-BB87-2239695B1D1A

Q28345359-8882271C-8B1A-4F40-A3F5-CA40205E89A5

Q28345359-ABDC326E-229C-4A91-858A-DAF7760A933F

Q28345359-B0386547-9EC9-4CE1-9AF4-CD7E25143007

Q28345359-FE6342B5-9BE9-48F0-82E3-05249CF8929E

P2888

Q28345359-5DC64282-D4C0-4F19-B9BE-F98C4A84AE16

P304

Q28345359-1ED4DE6D-5BA2-4266-9730-DAF98098FA7B

P31

Q28345359-AB706FC6-D6B7-4762-B5E3-D4D6AE013077

P356

Q28345359-2E81882E-26A9-4763-9AD1-842DA879333D

P407

Q28345359-9E294D2B-DA41-4D02-8252-3CE9570CCF96

P433

Q28345359-7F12D4FE-4C22-4EFE-909B-204780F204E3

P478

Q28345359-A46E608C-94B1-486F-B0F9-90A466A5AF83

P50

Q28345359-7B6733B5-DE62-4258-81F0-C728C423A6FD

P577

Q28345359-1FD52F25-36CB-4BF8-9119-A7B7AAD85E16

P5875

Q28345359-F83BFDDA-98EA-4FA9-9DDC-E0713E654175

P6179

Q28345359-D97B6080-1F6B-4CEB-A177-1653B5A5AB72

P698

Q28345359-02643022-67CA-4BEA-AE6B-8918E9E310D4

P921

Q28345359-048D6A50-8352-4124-8924-A52296427635

Q28345359-5DDA406A-3442-4A16-8566-2D56AA200222

P932

Q28345359-22045191-5D30-49E6-BD1E-93493A4AA0F4

P356

P1433

British Journal of Cancer

P1476

Pharmacokinetics of anastrozol ...... r in combination' (ATAC) trial

@en

P2093

ATAC Trialists' Group

http://www.w3.org/2001/XMLSchema#string

I Jackson

http://www.w3.org/2001/XMLSchema#string

J Cuzick

http://www.w3.org/2001/XMLSchema#string

M Dowsett

http://www.w3.org/2001/XMLSchema#string

P2860

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

Recent advances in endocrine therapy of breast cancer.

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.

Use of tamoxifen for breast cancer: twenty-eight years later.

The relevance of preclinical models to the treatment of postmenopausal breast cancer.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Source of estrogen production in postmenopausal women.

P2888

P304

317-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2001.1925

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11856501

http://www.w3.org/2001/XMLSchema#string

P6179

1029547431

http://www.w3.org/2001/XMLSchema#string

P698

11487258

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

2364083

http://www.w3.org/2001/XMLSchema#string